Clinical trial NCT05634499: A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Official title: A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Endometrial Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2022-12-02
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.


Eligibility criteria: Inclusion Criteria:

* Confirmed Grade 1 endometrial cancer (EC) of endometrioid histology for which participants are willing to receive 6-cycles of study therapy. An endometrial biopsy (EMB) or dilation and curettage (D\&C) fresh collected within the screening period or archival sample collected within 3 months prior to screening must be provided to a central laboratory for histologic confirmation to determine eligibility.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Magnetic resonance imaging (MRI)-confirmation of non-deeply invasive tumor (\<50% myometrial invasion)
* MRI or computed tomography (CT)-confirmation of no extrauterine disease
* Willing to undergo a minimum of 6 continuous cycles of therapy before decision on surgery
* No prior treatment for endometrial cancer
* Able and willing to take oral medications
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
* Adequate hematologic and end-organ function, as defined in the protocol
* Negative HIV test at screening, with the following exception: Patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ≥200/μL, and have an undetectable viral load.
* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 30 days after the final dose of giredestrant, as defined in the protocol

Exclusion Criteria:

* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 30 days after the final dose of giredestrant or within the time period specified per local prescribing guidelines after the final dose of the investigator's choice of endocrine therapy
* Participants with non-endometrioid histologies, such as serous, clear cell, and mixed
* Treatment with investigational therapy within 28 days prior to initiation of study enrollment
* Treatment for cancer including but not limited to, chemotherapy, immunotherapy, cyclin-dependent kinase (CDK)4/6 inhibitors, endocrine therapy, biologic therapy, or herbal therapy within 28 days prior to the initiation of study enrollment
* Any gastrointestinal condition causing malabsorption or obstruction (e.g., celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)
* Known hypersensitivity to giredestrant or its excipients
* Known intercurrent illness or psychiatric illness/social situations that will limit compliance with study requirements
* Evidence or high suspicion of metastatic/extrauterine disease at enrollment
* Unwilling or unable to comply with study-related procedures, including all endometrial sampling/biopsies
* Planned surgery, either for the treatment of cancer or any other surgery, during the study treatment period and up to 10 days after the completion of study treatment
* Serious infections requiring IV antibiotics within 7 days prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact participant safety
* Participants who have clinically significant liver disease consistent with Child-Pugh Class B or C, including active hepatitis (e.g., hepatitis B virus \[HBV\] or hepatitis C virus \[HCV\]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis, as defined in the protocol
* Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment
* Any serious medical condition or abnormality in clinical laboratory tests that precludes the participant's safe participation in and completion of the study
* History of other malignancy within 5 years prior to screening, except for those with an expected negligible risk for metastases or death (e.g., 5-year overall survival 90%) after curative treatment
* Active tuberculosis
* Severe infection per investigator judgment at the time of enrollment, including but not limited to, use of systemic antibiotics, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact participant safety
* Significant cardiovascular disease, such as cardiac disease New York Heart Association Class II or greater, myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
* Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
* Major surgical procedure other than for diagnosis within 28 days prior to enrollment or anticipation of need for a major surgical procedure during the study
* Prior allogeneic bone marrow transplantation or solid organ transplant
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk for treatment complications illnesses or conditions that interfere with the participant's capacity to understand, follow, and/or comply with study procedures

Primary outcomes:
measure: Percentage of Participants Who Have Regression at 6 Months
timeFrame: Baseline, 6 Months
measure: Number of Participants with at Least One Adverse Event, with Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)
timeFrame: From Baseline until 30 days after the final dose of study drug (up to 1 year, 6 months)
Secondary outcomes:
measure: Percentage of Participants Who Have Complete Regression at 6 Months
timeFrame: Baseline, 6 Months
measure: Median Duration of Regression
timeFrame: From first regression to first relapse (up to 1 year, 6 months)
measure: Median Time to First Regression
timeFrame: From first study treatment to first regression (up to 1 year, 6 months)
measure: Median Time to Relapse or Loss of Clinical Benefit
timeFrame: From first study treatment to relapse or loss of clinical benefit, whichever occurs first (up to 1 year, 6 months)
measure: Plasma Concentration of Giredestrant at Specified Timepoints
timeFrame: Predose on Day 1 of Cycles 1, 2, 3, 4, and 6; 3-4 hours Postdose on Day 1 of Cycles 1 and 2 (each cycle is 28 days)
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: Miami Beach
country: United States
facility: Mount Sinai Medical Center
state: Florida
city: Minneapolis
country: United States
facility: Minnesota Oncology Minneapolis
state: Minnesota
city: Englewood
country: United States
facility: Englewood Health/Hematology Oncology Practice of Englewood (HOPE)
state: New Jersey
city: Pittsburgh
country: United States
facility: Western Pennsylvania Hospital
state: Pennsylvania
city: Fort Worth
country: United States
facility: Texas Oncology, P.A. - Fort Worth
state: Texas
city: Norfolk
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
city: Montreal
country: Canada
facility: McGill University Health Centre - Glen Site
state: Quebec
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
state: Emilia-Romagna
city: Gliwice
country: Poland
facility: Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice
city: Kielce
country: Poland
facility: Swietokrzyskie Centrum Onkologii
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: